Document is current
Any future updates will be listed below
-
Authors
Shaw, Timothy I. https://orcid.org/0000-0002-9316-1924
Wagner, Jessica https://orcid.org/0000-0003-2587-3310
Tian, Liqing https://orcid.org/0000-0001-9921-0603
Wickman, Elizabeth https://orcid.org/0000-0001-7086-9084
Poudel, Suresh
Wang, Jian
Paul, Robin https://orcid.org/0000-0003-3727-8025
Koo, Selene C. https://orcid.org/0000-0001-8459-2469
Lu, Meifen
Sheppard, Heather
Fan, Yiping
O’Neill, Francis H. https://orcid.org/0000-0003-4978-3969
Lau, Ching C.
Zhou, Xin https://orcid.org/0000-0003-3979-8200
Zhang, Jinghui https://orcid.org/0000-0003-3350-9682
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1F31CA257757-01A1)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R01CA216391)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA076292, P30CA021765)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Alex’s Lemonade Stand Foundation for Childhood Cancer (n/a)
Alliance for Cancer Gene Therapy (n/a)
- License Information
-
More Information
Article History
Received: 13 November 2023
Accepted: 9 April 2024
First Online: 3 May 2024
Competing interests
: T.S., J.W., E.W., J.Z., and S.G. have patent applications in the fields of T-cell and gene therapy for cancer. The following two patent applications are directly related to the manuscript: (i) Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (COL11A1), WO/2022/147075, PCT/US2021/065445 (Inventors: S.G., J.W., E.W., T.S., J.Z.; Institution: St. Jude Children’s Research Hospital), and (ii) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors, WO/2021/016091, No.PCT/US2021/065445 (Inventors: S.G., J.W., T.S., J.Z.; Institution: St. Jude Children’s Research Hospital). S.G. is a member of the Scientific Advisory Board of Be Biopharma and CARGO, and the Data and Safety Monitoring Board (DSMB) of Immatics and has received honoraria from TESSA Therapeutics within the last year. The remaining authors declare no competing interests.
